Please assess the completion status of the following clinical trial:

Trial Title: A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant females (18-26 weeks of gestation)~* documented HIV-1 infection~* Receiving darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine at the time of study entry~* Willing to remain on darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine as well as a background regimen, for the duration of the study, including 12 weeks postpartum~* Able to comply with the protocol requirements and to provide written informed consent.~Exclusion Criteria:~* Patients with any currently active acquired immune deficiency syndrome (AIDS) defining illness and AIDS-related opportunistic infection~* Patients using cytokine inhibitors (e.g., thalidomide), anabolic hormones, cytokines (e.g., IL-2, INF), efavirenz, hydroxyurea, oral hypoglycemics, systemic chemotherapy or known teratogenic agent~* Use of an investigational agent within 90 days~* Any known fetal anomaly~* Any current obstetric complication, including multiple gestations and pre-term labor~* Hepatitis B and/or C virus infection~* Grade 2 or higher anemia~* Thyroid disease~* Uncontrolled Diabetes Mellitus Types I and II, or gestational diabetes, as determined by the investigator

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Darunavir 600 /Ritonavir 100 (Type: EXPERIMENTAL): TMC114 (darunavir) Two 300 milligram (mg) or one 600 mg tablet twice daily up to 12 weeks postpartum / ritonavir one 100 mg tablet twice daily with darunavir up to 12 weeks postpartum.
- Group 2: Darunavir 800/Ritonavir 100 (Type: EXPERIMENTAL): TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum/ ritonavir one 100 mg tablet once daily with darunavir up to 12 weeks postpartum.
- Group 3: Etravirine (Type: EXPERIMENTAL): TMC125 (etravirine) 200 mg (1\*200 mg/2\*100 mg) tablets twice daily up to 12 weeks postpartum.
- Group 4: Rilpivirine (Type: EXPERIMENTAL): TMC278 (rilpivirine) One 25 mg tablet once daily up to 12 weeks postpartum.
- Group 5: Darunavir 800/Cobicistat 150 (Type: EXPERIMENTAL): Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.

Based on this trial design, predict the completion outcome and termination type (if applicable).